Advertisement
Screener

Definium Therapeutics, Inc. (DFTX) Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3

2.8 / 5 stars · 68/120 Roast Me

Definium Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3

Definium Therapeutics, Inc. (DFTX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2026-08-06

  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2026-06-30 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2026-03-31 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2025-12-31 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2025-09-30 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2024 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2023 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2022 was $0.00.
  • Definium Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2021 was $0.00.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$0.00
10-Q · filed 2026-08-06
$0.00
derived: sum of 3 quarters · filed 2026-08-06
$0.00
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$0.00
10-Q · filed 2026-05-07
$0.00
derived: sum of 2 quarters · filed 2026-08-06
$0.00
derived: sum of 3 quarters · filed 2026-08-06
$0.00
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$0.00
derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06
$0.00
derived: sum of 2 quarters · filed 2026-08-06
$0.00
derived: sum of 3 quarters · filed 2026-08-06
$0.00
10-Q · filed 2026-08-06
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$0.00
derived: sum of 2 quarters · filed 2025-11-06
$0.00
10-Q · filed 2025-11-06
$0.00
derived: sum of 4 quarters · filed 2026-02-26
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
$0.00
10-Q · filed 2025-07-31
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$0.00
derived: sum of 4 quarters · filed 2026-02-26
2025-03-31$0.00
10-Q · filed 2025-05-08
$0.00
derived: sum of 2 quarters · filed 2026-02-26
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$0.00
derived: sum of 4 quarters · filed 2026-02-26
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$0.00
derived: sum of 2 quarters · filed 2026-02-26
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$0.00
10-K · filed 2026-02-26
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$0.00
derived: sum of 2 quarters · filed 2024-11-07
$0.00
10-Q · filed 2024-11-07
$0.00
derived: sum of 4 quarters · filed 2025-03-06
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$0.00
10-Q · filed 2024-08-13
$0.00
derived: sum of 3 quarters · filed 2025-03-06
$0.00
derived: sum of 4 quarters · filed 2025-03-06
2024-03-31$0.00
10-Q · filed 2024-05-08
$0.00
derived: sum of 2 quarters · filed 2025-03-06
$0.00
derived: sum of 3 quarters · filed 2025-03-06
$0.00
derived: sum of 4 quarters · filed 2025-03-06
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$0.00
derived: sum of 2 quarters · filed 2025-03-06
$0.00
derived: sum of 3 quarters · filed 2025-03-06
$0.00
10-K · filed 2025-03-06
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$0.00
derived: sum of 2 quarters · filed 2023-11-02
$0.00
10-Q · filed 2023-11-02
$0.00
derived: sum of 4 quarters · filed 2024-02-28
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$0.00
10-Q · filed 2023-08-03
$0.00
derived: sum of 3 quarters · filed 2024-02-28
$0.00
derived: sum of 4 quarters · filed 2024-02-28
2023-03-31$0.00
10-Q · filed 2023-05-04
$0.00
derived: sum of 2 quarters · filed 2024-02-28
$0.00
derived: sum of 3 quarters · filed 2024-02-28
$0.00
derived: sum of 4 quarters · filed 2024-02-28
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$0.00
derived: sum of 2 quarters · filed 2024-02-28
$0.00
derived: sum of 3 quarters · filed 2024-02-28
$0.00
10-K · filed 2024-02-28
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$0.00
10-Q · filed 2022-11-10
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$0.00
10-Q · filed 2022-08-11
2022-03-31$0.00
10-Q · filed 2022-05-16
2021-12-31$0.00
10-K · filed 2023-03-09
2020-12-31$0.00
10-K · filed 2022-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cronos Group Inc. (CRON)$1.223B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B